PDCD1 and pancreatic neoplasm: The low sensitivity of pancreatic cancer to PD-1/PD-L1 blockers contrasts the weak role of PD-L1 in the pancreatic TME, in which a highly dense tissue barrier might make exogenous intervention difficult to inhibit PD-L1 function [54].